In fact, the side effects of anti-VEGF therapies for human cancers are downstream effects of the suppression of VEGF signaling in endothelial cells of normal organs, causing bleeding, hypertension and asymptomatic proteinuria [32]. This evidence concerns the gene VEGFA and cancer.